Life Science & Biotech

Lilly to pay $400M to repurchase Cymbalta rights

April 19, 2010
Bloomberg News
Eli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European partner Boehringer Ingelheim for an initial payment of $400 million.
More

Lilly sues Hospira over generic version of Gemzar

March 24, 2010
Bloomberg News
Indianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the cancer drug Gemzar before a patent on the medicine expires in 2013.
More

Ariad loses $65M patent appeal against Eli Lilly

March 22, 2010
Bloomberg News
Monday's decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly's osteoporosis drug Evista and sepsis medicine Xigris.
More

FDA says 'not yet' on Lilly's once-weekly Byetta

March 15, 2010
J.K. Wall
Regulators won't require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling, manufacturing processes.
More

Eli Lilly to buy European rights to Pfizer animal products

March 8, 2010
Scott Olson
The acquisition will benefit Elanco, Lilly's animal health division in Greenfield, which has become increasingly important to Lilly as it braces for patent-protection losses.
More

Dow AgroSciences considered expansion elsewhere

March 5, 2010
Peter Schnitzler
Agricultural biotech firm hired a site-selection consultant and considered other cities around the world for its $340 million expansion.
More

Dow Agro plans $340M expansion, 577 new jobs

March 4, 2010
Peter Schnitzler
The investment will greatly expand the company's research and development capacity and is a major win for the Indiana life sciences industry. Dow AgroSciences expects most of the positions to pay between $65,000 and $95,000 annually.
More

Cornelius to retire as Bristol-Myers Squibb CEO

March 3, 2010
 IBJ Staff and Associated Press
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
More

Dow Agro plans 'major' expansion announcement

March 3, 2010
Peter Schnitzler
Local Dow Chemical subsidiary expects to launch five new biotech products by 2012.
More

Lilly to shift more employees to Covance

February 26, 2010
J.K. Wall
Greenfield Labs operation expects to add 17 Eli Lilly and Co. workers after taking over staff of 264 in 2008 acquisition.
More

Indiana companies that serve pharmaceutical industry grew in 2009

February 20, 2010
 IBJ Staff
The firms continued to grow over the last year but face increasing challenges, according to a new report by Indianapolis-based life sciences trade group BioCrossroads.
More

Vortek Surgical moving HQ to Brownsburg, adding 60 jobs

February 18, 2010
 IBJ Staff
Indianapolis-based Vortek Surgical LLC will relocate to Brownsburg, expanding its headquarters, manufacturing and distribution operations and creating more than 60 jobs in the next three years.
More

Bioanalytical Systems reports quarterly loss

February 17, 2010
Bioanalytical Systems Inc., a West Lafayette-based life sciences contract research firm, on Wednesday reported a loss of $1.4 million for its fiscal first quarter.
More

Dow Agro CEO says pipeline of products strong

February 10, 2010
Dow AgroSciences CEO Antonio Galindez told investors Wednesday morning that the company plans to launch five products by 2013 that could increase annual revenue by $800 million.
More

Report: State's pharmaceutical contractors continue to grow

February 10, 2010
A report set to be released Wednesday by local life sciences industry group BioCrossroads says Indiana companies providing contract pharmaceutical research and manufacturing services are weathering the economic downturn and are growing.
More

Health care venture capital swoons in Indy, holds steady statewide

February 6, 2010
 IBJ Staff
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009.
More

Health firms still attracting venture capital

February 3, 2010
J.K. Wall
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009. That trend hit Indianapolis, but the rest of the state actually saw an increase.
More

Dow AgroSciences profit falls despite revenue increase

February 2, 2010
 IBJ Staff
Indianapolis-based Dow AgroSciences said Tuesday it posted a profit of $69 million in the fourth quarter, down 19 percent from the prior year because of increased research and development spending and higher administrative expenses. Revenue was up 17 percent.
More

City of Greenwood might fund launch of insulin makerRestricted Content

January 30, 2010
Kathleen McLaughlin
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin, a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.
More

TechPoint accepting nominations for Mira technology awards

January 23, 2010
 IBJ Staff
The awards are meant to showcase Indiana's high-tech success stories and raise the profile of the tech community.
More

Dow Agro in legal skirmish over canola oil

January 14, 2010
Bloomberg News
Indianapolis-based Dow AgroSciences LLC has sued Cooper Industries Plc in an effort to clarify its rights to make a canola-based fluid used in electrical transformers.
More

Entrepreneur says quality of venture capital as important as quantity

January 2, 2010
 IBJ Staff
Jim Pearson knows a thing or two about raising money from venture capitalists. And he has some advice for BioCrossroads: Teach entrepreneurs the value of money.
More

First Indiana Future Fund off to a slow startRestricted Content

December 19, 2009
Peter Schnitzler
More than half of the venture capital fund's original investors took a pass on its $58 million successor, the newly launched INext.
More

New BioCrossroads venture fund raises $58 million

December 16, 2009
Peter Schnitzler
The new INext fund is the successor to the $73 million Indiana Future Fund, which the life science initiative raised in 2003.
More

Senate rejects drug-importation proposal

December 16, 2009
 IBJ Staff and Associated Press
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers such as Indianapolis-based Eli Lilly and Co. a victory.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. These liberals are out of control. They want to drive our economy into the ground and double and triple our electric bills. Sierra Club, stay out of Indy!

  2. These activist liberal judges have gotten out of control. Thankfully we have a sensible supreme court that overturns their absurd rulings!

  3. Maybe they shouldn't be throwing money at the IRL or whatever they call it now. Probably should save that money for actual operations.

  4. For you central Indiana folks that don't know what a good pizza is, Aurelio's will take care of that. There are some good pizza places in central Indiana but nothing like this!!!

  5. I am troubled with this whole string of comments as I am not sure anyone pointed out that many of the "high paying" positions have been eliminated identified by asterisks as of fiscal year 2012. That indicates to me that the hospitals are making responsible yet difficult decisions and eliminating heavy paying positions. To make this more problematic, we have created a society of "entitlement" where individuals believe they should receive free services at no cost to them. I have yet to get a house repair done at no cost nor have I taken my car that is out of warranty for repair for free repair expecting the government to pay for it even though it is the second largest investment one makes in their life besides purchasing a home. Yet, we continue to hear verbal and aggressive abuse from the consumer who expects free services and have to reward them as a result of HCAHPS surveys which we have no influence over as it is 3rd party required by CMS. Peel the onion and get to the root of the problem...you will find that society has created the problem and our current political landscape and not the people who were fortunate to lead healthcare in the right direction before becoming distorted. As a side note, I had a friend sit in an ED in Canada for nearly two days prior to being evaluated and then finally...3 months later got a CT of the head. You pay for what you get...

ADVERTISEMENT